Feb. 6, 2012
/PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that
, Global Head, Late Phase Clinical Trials and
, Ph.D., MS.c., Vice President, Global Research Operations at PAREXEL will address innovative approaches to late stage development at the Summit for Clinical Ops Executives (
), to be held
February 7-9, 2012
. Attendees can learn about customized strategic and scientific solutions, provided by the
PAREXEL PACE™ (Peri-Approval Clinical Excellence) group
, to facilitate the transition from product development to commercialization in a seamless and cost-effective manner, by visiting the PAREXEL
on the exhibit floor.
During SCOPE, Ms. Tandon will provide opening remarks for the session entitled "Electronic Health Records and Clinical Trials." The session, which will be held on
Tuesday, February 7
, includes presentations from Pfizer, Incyte Corporation, and the Medicines and Healthcare products Regulatory Agency (MHRA).
Other program sessions being presented by PAREXEL experts include:
Tuesday, February 7, 4:30 p.m. and Wednesday, February 8, 4:20 p.m.
- "New Challenges Call for Innovative Approaches to Patient Recruitment and Retention for Post Marketing Trials," in two interactive breakout discussion groups
Facilitated by Ms. Tandon and Dr. Eriksson, these interactive discussions will assist attendees in understanding how effective strategies for emerging areas, including engagement in social media and use of electronic medical records, can offer benefits to the post marketing research enterprise and patient community. They will highlight trends driving the need for cost efficient patient recruitment and retention approaches.
Wednesday, February 8, 11:35 a.m.
- "Conducting Phase IIIB/IV Clinical Trials in a Changing Drug Environment," in the session Utilization of Patient-Level Data and Patient Reported Outcomes in Trials
Ms. Tandon will discuss industry dynamics that have placed increasing emphasis on the use of late phase clinical trial data. She will examine innovative and cost efficient tools and methodologies to conduct post marketing trials to ensure higher data quality, and accelerate better decision-making.